Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814910 | 0.85 | ALDH1A1 (0.58) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL1810666 | 0.82 | RAB9A (0.71) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL1817201 | 0.77 | SMN1; SMN2 (0.55) | LCLAT1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1811042 | 0.77 | KCNK3 (0.60) | RAB9AKMT2AMEN1MAPTKDM4E | |
| SCHEMBL4599740 | 0.77 | PRKCI (0.67) | LCLAT1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1814174 | 0.77 | KMT2A (0.69) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL1810078 | 0.77 | RAB9A (0.59) | LCLAT1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL2105318 | 0.76 | LCLAT1 (0.52) | LCLAT1NPC1KMT2AMEN1MAPT | |
| Hydrochloric Acid SCHEMBL2105320 | 0.76 | SMN1; SMN2 (0.54) | LCLAT1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL4600539 | 0.76 | KMT2A (0.63) | RAB9ANPC1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2318358-A2 | ACYLAMINOBENZAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010015355-A2 | NOVEL ACYLAMINOBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | KCNB1, KCNA5, KCNA7 | LCLAT1 1879/4885RAB9A 742/4885NPC1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.